Dose Reduction of Lopinavir in Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-04-30

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the pharmacokinetics of low-dose and standard dose, lopinavir/ritonavir in ARV PI naive HIV-1 infected Thai children.

To study clinical and immunological efficacy after 48 weeks of lopinavir/ritonavir in PI naïve HIV-1 infected Thai children

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children

NCT01139905

HIV-1 Infections

COMPLETED PHASE2

Lopinavir (LPV) Dose Reduction

NCT01159275

HIV-1 Infections

COMPLETED PHASE1/PHASE2

Lopinavir/Ritonavir Monotherapy in Children

NCT00626301

HIV Infections

COMPLETED PHASE4

A PK and Salvage Study for Children With HIV-infection

NCT00476359

HIV Infections

COMPLETED PHASE4

Lopinavir/Ritonavir (Kaletra) PK in Children

NCT00810108

HIV/AIDS Treatment HIV Infections

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In 2002, the Thai Ministry of Public Health (MOPH) launched the National Access to Antiretroviral Program for People living with HIV/AIDS (NAPHA) with the aim of providing treatment to all Thai patients who needed antiretroviral treatment. By the end of 2005, 80,000 HIV-infected Thais were treated in the NAPHA program, including about 6,000 children. The antiretroviral treatment regimen consists of three antiretroviral drugs (ARV). The first-line regimen used in NAPHA are mainly generic drugs produced by Thai government pharmaceutical organization (GPO), including a fixed-drug combination of stavudine, lamivudine, and nevirapine (GPOvir);and a fixed-drug combination of zidovudine, lamivudine, and nevirapine (GPOvir-Z). Majority of patients respond very well with first-line regimen(1,2), however about 15% of patients have drug resistance to first-line regimen and require second-line regimen(3). The protease inhibitors (PIs) is used as a second-line regimen, however there are limitations in terms of cost and metabolic complications(4).

Lopinavir/ritonavir is the most widely use protease inhibitors in children because of its high efficacy and a syrup formulation that easy to use in small children. There is evidence supported that the recommended dose according to US-FDA or EU guidelines resulting in much higher plasma blood level in Thai children. Data from 19 Thai children demonstrated Cmin of 5.9 mg/L compare to 3.4 mg/L in US children when use the same dose (the minimum acceptable Cmin is 1.0 mg/L) (5,6). There is a study HIVNAT019, which demonstrated acceptable LPV plasma concentration and treatment outcome in Thai HIV-infected adult when use reduced dose of LPV/r 266mg/66 mg compare to standard dose of 400mg/100mg (7).

Therefore, the study of pharmacokinetic of low dose of LPV/r in Thai HIV-infected children is very important to assess the safety and efficacy of this strategy. This will lead to appropriate ARV dose in children to reduce long-term adverse events, and also reduce the ARV cost.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Lopinavir/ritonavir standard dose + zidovudine and lamivudine

Group Type ACTIVE_COMPARATOR

Lopinavir/ritonavir standard dose According to WHO simplified dosing table

Intervention Type DRUG

* BW 6-7.9 kg: 1.5 mL oral q 12 hr
* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr
* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr
* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr
* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr
* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr
* BW \> 35 kg: 5.0 ml oral q 12 hr

Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)

2

Lopinavir/ritonavir low dose (70% of standard dose) + zidovudine and lamivudine

Group Type ACTIVE_COMPARATOR

Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)

Intervention Type DRUG

* BW 6-7.9 kg: 1.0 mL oral q 12 hr
* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr
* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr
* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr
* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr
* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr
* BW \> 35 kg: 3.5 ml oral q 12 h

Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lopinavir/ritonavir standard dose According to WHO simplified dosing table

* BW 6-7.9 kg: 1.5 mL oral q 12 hr
* BW 8.0-16.9 kg: 2.0 ml oral q 12 hr
* BW 17.0-19.9 kg: 2.5 ml oral q 12 hr
* BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr
* BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr
* BW 30.0-34.9 kg: 4.0 ml oral q 12 hr
* BW \> 35 kg: 5.0 ml oral q 12 hr

Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)

Intervention Type DRUG

Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)

* BW 6-7.9 kg: 1.0 mL oral q 12 hr
* BW 8.0-16.9 kg: 1.5 ml oral q 12 hr
* BW 17.0-19.9 kg: 1.8 ml oral q 12 hr
* BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr
* BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr
* BW 30.0-34.9 kg: 3.0 ml oral q 12 hr
* BW \> 35 kg: 3.5 ml oral q 12 h

Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 2- 18 years old
* Documented positive test for HIV-1 infection
* PI-naïve
* HIV RNA viral load \> 1,000 copies
* Written informed consent

Exclusion Criteria

* Active opportunistic infection
* Relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion.
* Use of concomitant medication that may interfere with the pharmacokinetics of lopinavir/ritonavir
* Pregnancy or lactating
* Inability to understand the nature and extent of the study and the procedures required.

Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No